A1LN34:BVMF
Alnylam Pharmaceuticals Inc Bdr
R$43.75
0.00%
(0.00) 1D
Nov 11, 4:56:00 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1LN34...
Open
R$42.76
High
R$43.75
Low
R$42.76
Mkt. cap
21.41B
Avg. vol.
4.88K
Volume
88.00
52-wk high
R$126.48
52-wk low
R$42.25
Shares outstanding
133.94M
No. of employees
2K
Open
R$42.76
High
R$43.75
Low
R$42.76
Mkt. cap
21.41B
Avg. vol.
4.88K
Volume
88.00
52-wk high
R$126.48
52-wk low
R$42.25
Shares outstanding
133.94M
No. of employees
2K
News stories
From web sources and news partners
Scrip
·
10 hours ago
Stock Watch: Lilly’s 52-Week High Meets Alnylam’s 52-Week Low
BioPharma Dive
·
1 week ago
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals Inc Bdr
CEO-
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitealnylam.com